Development and Roll-Out of A Coronavirus Disease 2019 Clinical Pathway for Standardized Qualified Care in Public Hospitals in Korea

Kwak, Mi Young; Jo, Eun Young; Chin, Bum Sik; Park, Se Eun; Yim, Jun; Lee, Jung Eun; Jo, Kyung Eun; Kim, So Hyun; Lee, Jeong Eun; Yoon, Young Kyung; Seo, Yu Bin; Jeong, Su Jin; Kang, Yu Min; Joo, Eun-Jeong; Yoon, Jong Hyun; Kim, Sun Bean; Kim, Ga Yeon; Kim, Min-Kyung

doi:10.3947/ic.2022.0026

Cited by 2 publications

(3 citation statements)

References 2 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29 This is concordant with the recommendations and management guidelines for COVID-19 in Korea and the US. 7 8…”

Section: Antiviral Treatment Optionsmentioning

confidence: 99%

See 1 more Smart Citation

Treatment Options for Patients With Mild-to-Moderate Coronavirus Disease 2019 in Korea

Jeon

Chin

2022

J Korean Med Sci

Self Cite

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) continues to threaten public health in Korea although several surges have passed in the past 3 years since 2019. Although patients with mild-to-moderate COVID-19 can usually recover at home, antiviral therapy to prevent disease progression and hospitalization is beneficial for those at high risk of progressing to severe COVID-19. The purpose of this article was to review how antivirals have been rolled out for the treatment of COVID-19 and how domestic and international guidelines for their use have evolved. Several evidence-based treatment guidelines have been developed in Korea, including those derived from domestic studies. Although many different antiviral agents were nominated as promising therapeutics at the onset of the pandemic, most failed to show efficacy in clinical trials. Currently, three types of antiviral agents—nirmatrelvir-ritonavir, molnupiravir, and remdesivir—are available in Korea to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Each antiviral has its advantages and disadvantages. For most individuals, nirmatrelvir/ritonavir is preferred because of its high efficacy and convenience of administration. When serious drug interactions occur or are expected with nirmatrelvir/ritonavir administration, 3 days of remdesivir treatment is shown to be a reasonable alternative. Molnupiravir may be prescribed with caution only if no other therapeutic options are available or acceptable.

show abstract

“…29 This is concordant with the recommendations and management guidelines for COVID-19 in Korea and the US. 7 8…”

Section: Antiviral Treatment Optionsmentioning

confidence: 99%

“… 4 5 For patients with increased risks of severe disease, antiviral therapy is the only option that can prevent hospitalization and disease progression and is recommended in most current guidelines for COVID-19 management. 6 7 8…”

Section: Introductionmentioning

confidence: 99%

Treatment Options for Patients With Mild-to-Moderate Coronavirus Disease 2019 in Korea

Jeon

Chin

2022

J Korean Med Sci

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, several studies supported the use of PCT in the global pandemic caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as coronavirus disease 2019 (COVID-19). Treatment with an antiviral agent against COVID-19 infection is recommended based on the severity of COVID-19 infection and host factors [ 56 ]. Routine use of empiric antibiotic therapy is not recommended unless there is evidence or suspicion of having bacterial co-infections.…”

Section: Impact Of Procalcitonin Guidancementioning

confidence: 99%

Clinical Utility of Procalcitonin on Antibiotic Stewardship: A Narrative Review

Kim

2022

Infect Chemother

View full text Add to dashboard Cite

Procalcitonin (PCT) was discovered as a useful marker for bacterial infection. Following its discovery, there have been a substantial number of clinical studies conducted to evaluate the presence of bacterial infections, and to guide antibiotic treatment by the stratified levels of PCT. Clinical evidence suggests that antibiotic treatment by PCT-guided antibiotic stewardship has been associated with a reduction in antibiotic usage without an increase in adverse outcomes. The use of PCT was approved by the Food and Drug Administration in the United States of America in 2017 to guide antibiotic treatment in sepsis and lower respiratory tract infections (LRTIs). In Korea, the use of PCT for sepsis and for pneumonia was approved in 2015 and 2022, respectively. This review will discuss the clinical utility of PCT on antibiotic stewardship in the management of sepsis and LRTIs including pneumonia.

show abstract

Development and Roll-Out of A Coronavirus Disease 2019 Clinical Pathway for Standardized Qualified Care in Public Hospitals in Korea

Cited by 2 publications

References 2 publications

Treatment Options for Patients With Mild-to-Moderate Coronavirus Disease 2019 in Korea

Treatment Options for Patients With Mild-to-Moderate Coronavirus Disease 2019 in Korea

Clinical Utility of Procalcitonin on Antibiotic Stewardship: A Narrative Review

Contact Info

Product

Resources

About